Weight-reducing medicine taking siraitia grosvenorii pomace water extract as active ingredient and application of weight-reducing medicine

Abstract

The invention discloses a weight-reducing medicine with siraitia grosvenorii pomace water extract as an active ingredient and application of the weight-reducing medicine, and belongs to the technical field of biological medicine. The weight-reducing medicine with the siraitia grosvenorii pomace water extract as the active ingredient has the effects of reducing fat deposition, delaying weight gain and the like, and can effectively reduce animal abdominal fat deposition, relieve liver fatty lesion, slow down animal weight gain and reduce the fat content in animal bodies after being added into animal feed or daily ration; good application prospects are realized.

Description

TECHNICAL FIELD

[0001] The present application relates to a weight loss drug, in particular to a weight loss drug suitable for reducing abdominal fat deposition and delaying weight gain of animals, and belongs to the technical field of biological medicine. BACKGROUND

[0002] In recent years, the problem of overnutrition and insufficient exercise of companion animals (such as dogs and cats) is becoming increasingly serious, leading to an increasing incidence of obesity in pets year by year. Studies have shown that pet obesity not only significantly reduces the quality of life, but also induces a variety of metabolic-related complications, including diabetes, non-alcoholic fatty liver disease (NAFLD), etc., and becomes a major hidden danger affecting modern pet health. There are various weight loss formula feeds and drugs on the market, but they usually have the problems of high cost and large side effects. Therefore, the development of natural, safe and long-term functional additives has become a research hotspot in the field of pet weight loss.

[0003] In the field of poultry breeding, fatty liver and fatty liver hemorrhagic syndrome (FLHS) occur widely in high-yield laying hens. The main pathological features are excessive fat deposition in the liver, fragile structure, easy to rupture, and severe cases can cause sudden death, causing significant economic losses. The incidence of the disease is showing an upward trend year by year, causing great economic losses to the poultry breeding industry.

[0004] In the production of traditional Chinese medicine industry, a large amount of medicinal fruit residues will be produced, and by-products such as momordica fruit residues are often treated as waste, which not only wastes resources but also brings environmental pressure. In fact, various Chinese medicinal fruit residues still contain active ingredients such as polysaccharides, saponins, and flavonoids, which have potential effects such as antioxidant and metabolic regulation. Therefore, how to resource utilization of fruit residues and fully tap the value of non-medicinal parts and fruit residues produced by tens of millions of mu of momordica production and deep processing has broad prospects. SUMMARY

[0005] In view of the technical defects of the prior art, the first object of the present application is to provide a weight loss drug with momordica fruit residue water extract as the active ingredient, which has the effects of reducing fat deposition and delaying weight gain.

[0006] The second object of the present application is to provide an application of a weight loss drug, which can effectively reduce abdominal fat deposition, alleviate liver fatty lesions, slow down weight gain, and reduce fat content in animals when added to animal feed or animal daily ration. For example, it can reduce the weight of abdominal fat of broilers, reduce the accumulation of fat in the abdomen, reduce the possibility of liver fatty lesions, and improve meat quality. It can also delay weight gain and reduce fat weight in mice, and has good application prospects.

[0007] In order to achieve the above technical purposes, the present application provides a weight loss drug, and the active ingredient of the drug is water extract of Siraitia grosvenorii pomace.

[0008] The water extract of Siraitia grosvenorii pomace of the present application is obtained by further hot water extraction of Siraitia grosvenorii pomace waste. The active ingredients obtained by extraction are mainly water-soluble components in Siraitia grosvenorii pomace, specifically polysaccharides, proteins, reducing sugars, dietary fibers, flavonoids and mogrosides contained in Siraitia grosvenorii. It is unexpectedly found that these active ingredients obtained by extraction have the effects of reducing fat deposition and slowing down weight gain.

[0009] As a preferred scheme, the polysaccharide content in the water extract of Siraitia grosvenorii pomace is 40.0-50.0%, the crude protein content is 1.5-3.0%, the reducing sugar content is 3.0-5.0%, the dietary fiber content is not higher than 1.0%, the total flavonoid content is 0.01-0.1%, and the mogrosides content is 1.0-2.5%. The polysaccharides in the water extract of Siraitia grosvenorii pomace of the present application are the main components, and also contain a small amount of proteins, reducing sugars and dietary fibers, and a small amount of flavonoids. The comprehensive effect of these components is to effectively reduce the fat deposition in the abdomen of animals, alleviate the fatty liver disease of animals, slow down the weight gain of animals, and reduce the fat content in animals.

[0010] As a preferred scheme, the weight loss drug has the effects of reducing fat deposition and slowing down weight gain.

[0011] As a preferred scheme, the water extract of Siraitia grosvenorii pomace is prepared by the following method: mixing Siraitia grosvenorii pomace with 60-80℃ hot water at a solid-liquid mass / volume ratio of 1:20-40, extracting for 3-5 h, filtering to collect the extract, and heating and concentrating to obtain the water extract of Siraitia grosvenorii pomace. The preferred extraction method can effectively obtain the water-soluble active ingredients of Siraitia grosvenorii pomace. It should be noted that the active ingredients extracted from Siraitia grosvenorii pomace under different solvent and temperature conditions are different, and the water extract of Siraitia grosvenorii pomace obtained by extraction with 60-80℃ hot water has the effects of reducing fat deposition and slowing down weight gain, which is an unpredictable effect.

[0012] As a preferred scheme, the weight loss drug further comprises pharmaceutical starch. The pharmaceutical starch is a conventional pharmaceutical excipient.

[0013] As a preferred scheme, the mass ratio of the pharmaceutical starch to the water extract of Siraitia grosvenorii pomace is 2-3:1.

[0014] The application also provides a use of the weight loss medicine, which is added in animal feed or animal daily ration, for reducing abdominal fat deposition or slowing down weight gain of animals. The active ingredient of the weight loss medicine of the application is the water extract of Momordica grosvenori residue, which is particularly suitable for pet obesity, or poultry fatty liver and fatty liver hemorrhage syndrome, such as the weight loss medicine can reduce the abdominal fat weight of broilers, reduce the accumulation of fat in the abdomen, reduce the possibility of fatty liver disease of the liver, and can improve the meat quality of poultry, delay the weight gain of animals, and reduce the fat weight in the body.

[0015] As a preferred scheme, the additive amount of the weight loss medicine in the animal feed or animal daily ration is 800-1600 mg / kg.

[0016] The specific preparation method of the weight loss medicine of the application is as follows:

[0017] 1) The dried and crushed Momordica grosvenori residue is heated at 70℃ for 4 h with water, the solid-liquid ratio is 1 kg:30 L, the extract is collected by filtration, and concentrated under reduced pressure to obtain the water extract of Momordica grosvenori residue;

[0018] 2) The water extract of Momordica grosvenori residue is used as the raw material, medicinal starch is selected as the auxiliary material, 75-85% ethanol solvent is used as the appropriate wetting agent, and the weight loss medicine is prepared according to the ratio of 1:2-3 of the raw material to the auxiliary material, the soft material reaches the standard of being kneaded into a ball and being scattered by touch, the soft material is first passed through a 16-mesh screen and dried in a 60℃ oven to obtain the weight loss medicine; the weight loss medicine can be further crushed for 5-10 minutes, the particle size can be passed through a 60-mesh screen, and then packed for use.

[0019] Compared with the prior art, the technical scheme of the application has the following beneficial technical effects:

[0020] The active ingredient of the weight loss medicine of the application is the water extract of Momordica grosvenori residue, which is a solid waste, has a wide source of raw materials, low cost, and can realize its resource utilization.

[0021] The weight loss medicine of the application added in the animal feed or animal daily ration can effectively reduce the abdominal fat deposition of animals, reduce the fatty liver disease of the liver, slow down the weight gain of animals, and reduce the fat content in the body of animals, which has a good application prospect. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 The relationship between the feed intake of the chicks in Example 2 and time.

[0023] Figure 2 The relationship between the feed intake of the mice in Example 3 and time.

[0024] Figure 3For the time course of body weight and terminal body weight of mice in Example 3.

[0025] Figure 4 For the time course of body fat of mice in Example 3.

[0026] Figure 5 For the time course of organ weight of mice in Example 3.

[0027] Figure 6 For the glucose tolerance test curve of mice in Example 3. DETAILED DESCRIPTION

[0028] The embodiments of the present application will be described in detail below with reference to the examples, so that the process of how the present application applies technical means to solve technical problems and achieve technical effects can be fully understood and implemented.

[0029] The momordica grosvenori residue involved in the following specific examples is provided by Hunan Huacheng Biological Resources Co., Ltd., which is mainly the residue left after the momordica grosvenori whole fruit is extracted by hot water and dried. The product prepared by extracting momordica grosvenori glycosides with momordica grosvenori as the main raw material is often used to relieve and treat pharyngitis, and a large amount of waste is generated during the preparation process, such as residual polysaccharides and fiber-rich skin residue, which are not utilized.

[0030] Example 1

[0031] 1. Preparation of momordica grosvenori residue extract granules

[0032] The momordica grosvenori residue is extracted by hot water extraction method, and the extraction conditions are as follows: extraction temperature 70°C; extraction time 4 h, and solid-liquid ratio 1 kg:30 L. The extraction liquid is collected by filtration, and concentrated under reduced pressure to a thick paste, to obtain momordica grosvenori residue water extract. With the momordica grosvenori residue water extract as the raw material, medicinal starch is selected as the auxiliary material, and 80% ethanol solvent is used as the appropriate wetting agent. The soft material is prepared according to the ratio of raw material to auxiliary material of 1:2.5. The soft material meets the standard of being kneaded into a ball and then scattered by touch. The soft material is first passed through a 16-mesh screen and then dried in a 60°C oven to obtain the weight loss medicine.

[0033] The weight loss medicine has the characteristics of slightly sweet, low hygroscopicity, easy to store, and can be used as an additive or added to drinking water.

[0034] Content determination of weight loss medicine:

[0035] Determination of polysaccharide content: The phenol-sulfuric acid method combined with ultraviolet spectrophotometer is used to determine the polysaccharide content. Glucose is used as the standard, and the absorbance is determined at 490 nm. After drawing the standard curve, the polysaccharide content in the sample is calculated. The results show that the polysaccharide content in the extract is 44.60%, which is one of the main active ingredients.

[0036] Crude protein determination: The Bradford method was used to determine the crude protein content, with bovine serum albumin as the standard. The absorbance was measured at 595 nm using a UV spectrophotometer. The results showed that the crude protein content was 2.19%.

[0037] Reducing sugar determination: The 3,5-dinitrosalicylic acid (DNS) method was used to determine the reducing sugar content. The absorbance of the reaction product was detected at 540 nm using a UV spectrophotometer, and quantified by a standard curve. The reducing sugar content was measured to be 4.25%.

[0038] Total dietary fiber determination: The GB 5009.88-2014 enzyme weight method was used to determine the total dietary fiber content. According to the standard, the sample was sequentially enzymatically digested with α-amylase, protease, and glucosidase, then filtered, washed, and dried at 105°C to constant weight. The total dietary fiber content in the sample was calculated by the weight difference. The total dietary fiber content in the sample was measured to be 0.31%.

[0039] Total flavonoid determination: High-performance liquid chromatography (HPLC) was used for quantitative analysis. The C18 chromatographic column was selected, the mobile phase was methanol-0.1% phosphoric acid solution (33:67), and the detection wavelength was set at 254 nm. By comparison with the standard, the total flavonoid content in the extract was calculated to be 0.0985% (calculated as rutin).

[0040] Rebunin determination: HPLC was also used to determine the rebunin content. The standard sample of mogroside V was used for comparison, the mobile phase was acetonitrile-water (23:77), the chromatographic detection wavelength was set at 203 nm, and quantitative analysis was performed according to the retention time and peak area. The results showed that the rebunin content was 1.76%.

[0041] Example 2

[0042] Lucuma fruit residue extract granules reduce abdominal fat deposition in broilers:

[0043] 1 Materials

[0044] 1.1 Test animals

[0045] Select 30 healthy normal AA white broiler chickens of the same batch with similar body weight, and raise them in a conventional 3-layer cage raising mode. The laying hens were randomly divided into 2 treatment groups (test group and control group), with 15 chickens in each treatment group.

[0046] 1.2 Test diet

[0047] The feed was corn-soybean meal type diet, provided by Hunan Rongmu Agricultural Technology Co., Ltd., wherein the control group was only fed with the basic diet; the test group added 1 g of Momordica grosvenorii pomace extract feed additive per kg of basic diet. The test duration was 5 weeks.

[0048] 2 Method

[0049] 2.1 Feeding management and clinical observation

[0050] The test was carried out in Changsha County, Changsha City, Hunan Province, using ladder type cages, and the test chickens were allowed to drink water freely. The chicken house was checked every morning at 8:00 and every afternoon at 17:00, and any dead chickens were immediately stopped from feeding and weighed, and the dead chickens were weighed and promptly buried.

[0051] The mental state, appetite, behavior, etc. of the test chickens were observed every day.

[0052] 2.2 Test index determination

[0053] During the test period, the chickens were weighed once a week (12 hours of fasting), and the average body weight of the chickens in each group was recorded. At 35 days of age, serum indicators were detected, liver index and abdominal fat rate were measured.

[0054] 2.3 Sample collection

[0055] 6 chickens were randomly selected from each group for the following treatment: weighing each chicken, blood sampling (12 hours of fasting before blood sampling), preparing serum. Evisceration, observing and recording the gross changes of internal organs of each group of chickens, dissecting the liver, weighing the liver; peeling off abdominal fat (abdominal fat and fat around the gizzard), weighing the abdominal fat.

[0056] 2.4 Sample determination

[0057] 2.4.1 Determination of liver coefficient: after evisceration, the liver was completely removed, and the liver coefficient was calculated. Liver coefficient = liver weight (g) / body weight (g) x 100.

[0058] 2.4.2 Determination of abdominal fat rate: adjust the zero of the electronic balance with a large flat dish; open the abdomen of the slaughtered and weighed chicken from the abdomen, first peel off the abdominal fat, then peel off the fat around the gizzard, and put it in the large flat dish; weigh and record the abdominal fat weight, and calculate the abdominal fat rate. Abdominal fat weight = abdominal fat weight + fat around the gizzard: abdominal fat rate (%) = abdominal fat weight (g) / live weight (g) x 100.

[0059] 2.4.4 Carcass traits: At the end of the 35-day-old trial, each chicken was weighed on an empty stomach. One chicken with a weight close to the average weight was selected from each replicate cage, bled, and its feathers, foot keratin, toe shells, and beak shells were removed before weighing. The abdominal fat was then separated and weighed. All internal organs were removed (leaving only the kidneys), and the eviscerated weight was weighed. Finally, the left breast and leg muscles were separated and weighed. The carcass trait indicators were calculated according to the method in NY / T 823-2004.

[0060] Dressing percentage (%) = Slaughter weight / Pre-slaughter weight × 100%

[0061] Semi-eviscerated yield (%) = Semi-eviscerated weight / Pre-slaughter body weight × 100%

[0062] Eviscerated weight (%) = Eviscerated weight / Pre-slaughter body weight × 100%

[0063] Pectoral muscle percentage (%) = (Left pectoral muscle weight × 2 / Total net chest weight) × 100%

[0064] Leg muscle percentage (%) = (Net muscle weight of left calf and thigh × 2 / Total net chest weight) × 100%

[0065] 2.4.5 Meat Quality: On day 36 of the experiment, right pectoral muscle and ipsilateral leg muscle were harvested to measure muscle shear force, meat color, and drip loss. Each sample was measured three times, and the average value was used to calculate the results. Shear force was measured using a digital display muscle tenderness meter. Colorimeter was used to measure the tenderness of the pectoral meat. , and Objective assessment of meat color. Meat color: 45 minutes after slaughter of the experimental chickens, the brightness of the breast and leg muscle samples was measured at three different locations at room temperature using a colorimeter. ), redness ( ) and yellowness ( The following parameters were used for testing: Drip loss rate: The upper half of the left pectoral muscle was taken, trimmed into appropriately sized pieces along the muscle fiber direction, weighed, and then suspended in an air-filled bag. After refrigeration at 4℃ for 24 hours, the surface moisture was removed, and the pieces were weighed again. Drip loss rate (%) = (Weight before refrigeration - Weight after refrigeration) / Weight before refrigeration × 100.

[0066] 3. Statistical processing of experimental data

[0067] 3.1 All experimental data were statistically analyzed using SPSS software according to statistical requirements. All data are expressed as mean ± standard error. ANOVA was used to test for significance of differences, and P < 0.05 was considered significant.

[0068] 4. Experimental Results

[0069] 4.1 Weight gain results

[0070] From Table 1, compared with the control group, the body weight of the group with 0.1% Momordica fruit residue extract particles in the diet decreased (P<0.05) at 21-35 days of age, and there was a significant difference.

[0071]

[0072] Note: The same row data with different letters represent significant differences (P<0.05), and the same letters or no letters represent no significant difference (P>0.05). The same as the following table.

[0073] 4.2 Intake

[0074] The group with added Momordica fruit residue extract particles had no significant difference in feed intake from 1-21 days of age compared with the control group, and the feed intake from 28-35 days of age was reduced by 14.61% and 7.3% compared with the control group.

[0075] 4.3 Liver, abdominal fat index

[0076] As shown in Table 2, the liver weight and abdominal fat weight of the group with 0.1% Momordica fruit residue extract in the diet were significantly lower than those of the control group (P<0.01).

[0077]

[0078] 4.4 Shear force and drip loss

[0079] As shown in Table 3, the muscle tenderness of the group with added 0.1% Momordica fruit residue extract particles increased, which was reflected in the decrease of the breast muscle shear force and leg muscle shear force compared with the control group (P<0.05); but there was no significant difference in water loss rate among the groups.

[0080]

[0081] 4.5 Meat quality

[0082] Compared with the control group, the group with added 0.1% Momordica fruit residue extract particles in the diet made the muscle color more tender, which was reflected in the significant decrease of the breast muscle value (P<0.05), the leg muscle value (P<0.05); value and value had no significant difference (P>0.05). Generally speaking, value and value are larger, value is smaller, and the meat color is better.

[0083]

[0084] 4.6 Carcass traits

[0085] The addition of Momordica grosvenori residue extract particles in the diet has no significant effect on the dressing percentage, half-evisceration percentage, whole-evisceration percentage, breast muscle percentage, and leg muscle percentage of broilers aged 1-35 days (P>0.05). However, the abdominal fat percentage of the broilers is reduced, and is significantly lower than that of the blank group (P<0.05).

[0086]

[0087] Compared with broilers fed with ordinary feed, broilers fed with feed added with Momordica grosvenori residue extract have the advantages of reduced abdominal fat percentage, improved meat quality, and reduced probability of fatty liver occurrence. The present application feeds broilers by adding Momordica grosvenori residue extract in the basic diet, which is simple to operate and can improve meat quality and reduce abdominal fat deposition.

[0088] Example 3:

[0089] Experiment of Momordica grosvenori residue extract particles delaying weight gain of mice:

[0090] 1 Materials

[0091] 1.1 Test animals

[0092] Male C57 mice with a body weight of more than 45 g were adaptively fed for one week before the test, and were randomly grouped at the time of the test.

[0093] 2 Methods

[0094] 2.1 Grouping and administration

[0095] The 24 male C57 mice were adaptively fed with ordinary breeding feed for one week, and were then randomly divided into a blank group (8 mice), a high-dose SSRE group (8 mice), and a low-dose SSRE group (8 mice). All groups were fed with ordinary feed, and the high-dose and low-dose groups were administered with the drug: the low-dose was 800 mg / kg, and the high-dose was 1600 mg / kg, with a gavage volume of 0.3 mL per mouse. The blank group was administered with an equal amount of normal saline, and they were allowed to freely eat and drink, for a duration of 4 weeks. The mice in each group were weighed every day to monitor their growth.

[0096] 2.2 Determination of test indicators

[0097] After the end of the test, the mice were fasted for 24 hours but were allowed to drink water, and then blood was collected by way of eye blood collection. Subsequently, the mice were euthanized by dislocation, and the organs and fat samples of the mice were collected and weighed.

[0098] 2.3 Sample determination

[0099] 2.3.1 Changes in body weight and feed intake

[0100] During the experiment, the body weight of mice was measured every day, and the change of food intake was recorded.

[0101] 2.3.2 Body fat weight change

[0102] The subcutaneous fat, epididymal fat and perirenal fat of mice were collected and weighed separately.

[0103] 2.3.3 Organ weight change

[0104] The organs of mice such as heart, liver, spleen, lung and kidney were collected and weighed separately.

[0105] 2.3.4 Glucose tolerance

[0106] 5 mice from each group were taken 12h before the experiment to measure the glucose tolerance of mice. The tail tip blood was taken to measure the basal blood glucose (0 min), and then intraperitoneal injection of glucose solution (1.5g / kg body weight, 25% glucose solution), respectively at 15, 30, 60, 90 and 120 min after injection, the tail vein blood samples of mice were collected by cutting the tail, and the blood glucose value was measured by blood glucose meter and recorded.

[0107] 3 Data processing and statistical analysis

[0108] All data were expressed as mean ± standard error (Means ± SEM), statistical analysis was completed by GraphPad Prism 9.5 and SPSS 27.0 software, data analysis used one-way analysis of variance (ANOVA) method for difference analysis, and the significant test standard was P < 0.05.

[0109] 4 Experimental results

[0110] 4.1 Food intake change

[0111] Compared with the blank group, the food intake of mice in the SSRE group by gavage began to decrease from the second week, and the food intake of mice in the high-dose group decreased more obviously, which was significantly different from the blank group.

[0112] 4.2 Body weight change

[0113] The body weight change of mice during the drug intervention period is shown in the figure, and the results show that during the whole drug cycle, different doses of SSRE administration can obviously alleviate the growth trend of mouse body weight (P < 0.05).

[0114] 4.3 Body fat weight change

[0115] The results of epididymal fat, perirenal fat, and groin fat weight in the treated mice are shown in the figure. It can be seen that compared with the control group, the epididymal fat in the high-dose SSRE treatment group was significantly reduced (P < 0.05), which proves that fat accumulation was reduced to a certain extent. Perirhinal fat and groin fat showed a decreasing trend, but the difference was not significant. Combined with the changes in body weight, it is suggested that SSRE may alleviate obesity by acting on fat.

[0116] 4.4 Changes in organ weight

[0117] The organ weight results of the mice in the drug-treated group are shown in the figure. It can be seen that, compared with the blank group, the weight of the liver was significantly reduced after high-dose SSRE administration (P<0.05). At the same time, although the weight of other organs decreased, there was no significant difference.

[0118] 4.5 Glucose tolerance

[0119] Glucose tolerance is the body's ability to regulate blood glucose concentration. This experiment was conducted to observe whether the ability of each group of mice to regulate blood glucose was abnormal. The results are shown in the figure. It shows that after SSRE administration intervention, the mice's ability to regulate blood glucose was stronger than that of the control group mice, and they could recover faster. This indicates that SSRE can effectively improve the glucose tolerance of mice.

[0120]

[0121] Note: Superscript " "Indicates comparison with group CK; " "Indicates P < 0.05;" " indicates P < 0.01; " "Indicates P < 0.001"

[0122] It should be noted that those skilled in the art can make various modifications and improvements without departing from the inventive concept, and these all fall within the scope of protection of this invention. Therefore, the scope of protection of this patent should be determined by the appended claims.

Claims

1. A weight loss medicament, characterized by: The active ingredient is water extract of momordica fruit residue. ​ 2. The weight loss drug according to claim 1, wherein: The polysaccharide content of the water extract of momordica fruit residue is 40.0-50.0%, the crude protein content is 1.5-3.0%, the reducing sugar content is 3.0-5.0%, the dietary fiber content is not higher than 1.0%, the total flavonoid content is 0.01-0.1%, and the mogroside content is 1.0-2.5%.

3. The weight loss drug according to claim 1 or 2, characterized in that: The weight loss drug has the effects of reducing fat deposition and slowing down weight gain.

4. The weight-reducing drug according to claim 1 or 2, characterized by: The water extract of momordica fruit residue is prepared by the following method: mixing momordica fruit residue with hot water at 60-80 DEG C according to the solid-liquid mass ratio of 1:20-40, extracting for 3-5 hours, filtering to collect the extract, and heating and concentrating to obtain the water extract of momordica fruit residue.

5. The weight-reducing drug according to claim 1 or 2, characterized by: It further comprises pharmaceutical starch.

6. The weight loss medicament according to claim 5, characterized in that: The mass ratio of the pharmaceutical starch to the water extract of momordica fruit residue is 2-3:

1.

7. The use of a weight loss drug according to any one of claims 1 to 6, characterized in that: It is added in animal feed or animal daily ration for reducing abdominal fat deposition or slowing down weight gain of animals. 8.The use of the water extract of Siraitia grosvenoridum pomace according to claim 7, characterized in that: The additive amount of the weight loss drug in animal feed or animal daily ration is 800-1600 mg / kg.

Images